{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:49:54Z","timestamp":1791596994689,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03212-x","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:46:32Z","timestamp":1791549992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between tumor volume reduction and treatment outcomes in nasopharyngeal carcinoma treated with PCE-based induction chemotherapy and concurrent chemoradiotherapy"],"prefix":"10.1007","author":[{"given":"Ya","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2219-6708","authenticated-orcid":false,"given":"Kenji","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenari","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"10192","key":"3212_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64\u201380","journal-title":"Lancet"},{"issue":"11","key":"3212_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509\u20131520","journal-title":"Lancet Oncol"},{"issue":"12","key":"3212_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381(12):1124\u20131135","journal-title":"N Engl J Med"},{"key":"3212_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","volume":"119","author":"Q Yang","year":"2019","unstructured":"Yang Q et al (2019) Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 119:87\u201396","journal-title":"Eur J Cancer"},{"issue":"1","key":"3212_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li WF et al (2019) Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer 145(1):295\u2013305","journal-title":"Int J Cancer"},{"issue":"11","key":"3212_CR6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1634\/theoncologist.2016-0105","volume":"21","author":"H Peng","year":"2016","unstructured":"Peng H et al (2016) Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial. Oncologist 21(11):1369\u20131376","journal-title":"Oncologist"},{"key":"3212_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104675","volume":"107","author":"DW Wen","year":"2020","unstructured":"Wen DW et al (2020) Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy. Oral Oncol 107:104675","journal-title":"Oral Oncol"},{"issue":"3","key":"3212_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/cam4.4477","volume":"11","author":"YT Jiang","year":"2022","unstructured":"Jiang YT et al (2022) Efficiency of high cumulative cisplatin dose in high- and low-risk patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Med 11(3):715\u2013727","journal-title":"Cancer Med"},{"issue":"1","key":"3212_CR9","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1002\/ONCO.13520","volume":"26","author":"M Mane","year":"2021","unstructured":"Mane M et al (2021) Meta-analysis on induction chemotherapy in locally advanced nasopharyngeal carcinoma. Oncologist 26(1):e130\u2013e141","journal-title":"Oncologist"},{"issue":"5","key":"3212_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/cam4.2852","volume":"9","author":"T Enokida","year":"2020","unstructured":"Enokida T et al (2020) A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Med 9(5):1671\u20131682","journal-title":"Cancer Med"},{"key":"3212_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571304","volume":"10","author":"Y Ueda","year":"2020","unstructured":"Ueda Y et al (2020) Combination treatment with paclitaxel, carboplatin, and cetuximab (PCE) as first-line treatment in patients with recurrent and\/or metastatic nasopharyngeal carcinoma. Front Oncol 10:571304","journal-title":"Front Oncol"},{"key":"3212_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951387","volume":"12","author":"N Takeshita","year":"2022","unstructured":"Takeshita N et al (2022) Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: a single-center, retrospective study. Front Oncol 12:951387","journal-title":"Front Oncol"},{"issue":"2","key":"3212_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.radonc.2008.02.003","volume":"87","author":"AW Lee","year":"2008","unstructured":"Lee AW et al (2008) Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol 87(2):204\u2013210","journal-title":"Radiother Oncol"},{"issue":"6","key":"3212_CR14","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/hed.25620","volume":"41","author":"ZZ Xiang","year":"2019","unstructured":"Xiang ZZ et al (2019) The prognostic value of volumetric reduction of the target lesions after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Head Neck 41(6):1863\u20131872","journal-title":"Head Neck"},{"issue":"1","key":"3212_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","volume":"126","author":"AW Lee","year":"2018","unstructured":"Lee AW et al (2018) International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother Oncol 126(1):25\u201336","journal-title":"Radiother Oncol"},{"issue":"2","key":"3212_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"3212_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104924","volume":"111","author":"YY Zeng","year":"2020","unstructured":"Zeng YY et al (2020) The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 111:104924","journal-title":"Oral Oncol"},{"issue":"10","key":"3212_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103933","volume":"9","author":"TSA Kwong","year":"2024","unstructured":"Kwong TSA et al (2024) Volumetric measurement to evaluate treatment response to induction chemotherapy on MRI outperformed RECIST guideline in outcome prediction in advanced nasopharyngeal carcinoma. ESMO Open 9(10):103933","journal-title":"ESMO Open"},{"issue":"3","key":"3212_CR19","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.21037\/qims-22-776","volume":"13","author":"D Yan","year":"2023","unstructured":"Yan D et al (2023) Induction chemotherapy reduces target volume drift in patients with locoregionally advanced nasopharyngeal carcinoma undergoing adaptive intensity-modulated radiotherapy: a retrospective cohort study. Quant Imaging Med Surg 13(3):1779\u20131791","journal-title":"Quant Imaging Med Surg"},{"issue":"2","key":"3212_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4143\/crt.2018.250","volume":"51","author":"L Wang","year":"2019","unstructured":"Wang L et al (2019) Reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Res Treat 51(2):685\u2013695","journal-title":"Cancer Res Treat"},{"issue":"1","key":"3212_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13014-022-02147-7","volume":"17","author":"T Jin","year":"2022","unstructured":"Jin T et al (2022) Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and\/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study. Radiat Oncol 17(1):176","journal-title":"Radiat Oncol"},{"issue":"7","key":"3212_CR22","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00432-020-03479-1","volume":"147","author":"Z Fei","year":"2021","unstructured":"Fei Z et al (2021) Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy. J Cancer Res Clin Oncol 147(7):2047\u20132055","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"3212_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","volume":"10","author":"JJ Pan","year":"2024","unstructured":"Pan JJ et al (2024) Ninth version of the AJCC and UICC nasopharyngeal cancer TNM staging classification. JAMA Oncol 10(12):1627\u20131635","journal-title":"JAMA Oncol"},{"issue":"1","key":"3212_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13014-025-02677-w","volume":"20","author":"S Dong","year":"2025","unstructured":"Dong S et al (2025) Beyond the ratio of tumor reduction: residual volume after induction chemotherapy emerges as the optimal biomarker in advanced nasopharyngeal cancer. Radiat Oncol 20(1):100","journal-title":"Radiat Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03212-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03212-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:02:10Z","timestamp":1791594130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03212-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":24,"alternative-id":["3212"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03212-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MN reports receiving honoraria from AstraZeneca, Illumina, and Sumitomo Heavy Industries. All other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Institutional Research Committee and the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients treated at National Cancer Center Japan Hospital East consented for the use of their anonymous data for research.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}